Contact: Nicole Napoli, email@example.com, 202-669-1465
WASHINGTON (May 15, 2021) -
Transcatheter left atrial appendage occlusion (LAAO) with a WATCHMAN device was associated with a low rate of stroke at one year even among older patients with atrial fibrillation (AFib) who faced a high risk for stroke or bleeding based on their previous health history, according to new data presented at the American College of Cardiology’s 70th Annual Scientific Session.
The WATCHMAN device, which blocks a small portion of the heart to help reduce the risk of a dangerous clot forming, was approved by the U.S. Food and Drug Administration in 2015. The device is used to reduce the risk of stroke in patients with AFib, a heart rhythm disorder, that is not caused by problems with the heart valve. It is also used in patients who require an alternative to the long-term use of anticoagulant medications, also known as blood thinners. Blood thinners are the primary medical option for reducing the risk of strokes, which are caused when a blood clot blocks an artery in the brain; however, they are not suitable for every patient due to drug interactions, side effects, logistical challenges or other reasons. The Centers for Medicare and Medicaid Services specify that patients receiving the WATCHMAN device should be at high risk for stroke and unable to take long-term oral anticoagulation.
The study, an analysis of a prospective registry of patients who received a WATCHMAN device via a catheter inserted into a blood vessel in the groin, found that in practice, the rate of ischemic stroke (the study’s primary endpoint) was generally on par with rates seen in clinical trials leading to the device’s approval. The findings offer reassurance that LAAO with the WATCHMAN device is likely effective for the patient population currently receiving it, according to the researchers.
“Based on these data, it seems like we’re doing the right thing,” said Matthew J. Price, MD, director of the cardiac catheterization laboratory at Scripps Clinic in La Jolla, California, and the study’s lead author. “The rate of ischemic stroke was low and supports the clinical effectiveness of transcatheter LAAO as it is currently applied in the U.S.”
The researchers analyzed real-world data from more than 36,000 procedures recorded in the ACC’s NCDR LAAO Registry, a registry that includes almost all LAAO procedures performed in the U.S. The study includes data from patients who received a WATCHMAN device in 2016, 2017 or 2018.
Patients in the registry were on average significantly older and at higher risk than those who were included in clinical trials for the WATCHMAN device, Price said. The average age of patients in the registry was 76 years; one-quarter of the patients had previously had a stroke, many were deemed to be at high risk for falls, and nearly 70% had previously experienced clinically relevant bleeding.
After a follow-up period of one year, an estimated 1.53% of patients in the registry suffered an ischemic stroke, 8.52% died and less than 0.7% experienced systemic embolism.
“I was actually a bit surprised by the relatively low event rates because the patients are substantially higher risk than those studied in clinical trials,” Price said. “However, all-cause mortality, as well as bleeding in the weeks following the procedure, were not infrequent—consistent with the co-morbidities of this patient population. This underscores the need to individualize one’s approach to stroke prevention so that patients reap the clinical benefit of stroke reduction.”
The rate of stroke was 77% lower than would be predicted by the patients’ CHA2DS2-VASc scores, a measure of stroke risk for patients with AFib. The study focused only on outcomes from LAAO procedures using the WATCHMAN device; future studies are planned to assess clinical efficacy at three and four years.
“By providing more data, I think this study continues to support LAAO in patients who are not suitable for long-term oral anticoagulation,” Price said. “The apparently low ischemic stroke event rates also provide support for ongoing clinical trials for LAAO versus oral anticoagulants in patients who are suitable for long-term oral anticoagulation.”
Because it is based on registry data, the study lacked a control group that did not receive the WATCHMAN device for comparison. However, the event rates observed in the study are consistent with those in other registry studies and clinical trials. Price said future research could focus on assessing LAAO in a broader patient population and on outcomes from new devices or techniques for performing the procedure.
The study was supported by the ACC’s NCDR and the National Heart, Lung, and Blood Institute.
Price will present the study, “One-year Clinical Outcomes Following Watchman Transcatheter Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Atrial Fibrillation: A Report from the NCDR LAAO Registry,” on Sunday, May 15, at 12:15 p.m. ET / 16:15 UTC, virtually.
ACC.21 will take place May 15-17 virtually, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC21 for the latest news from the meeting.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit ACC.org.